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Background: The aim of this study was to describe the effect of pretreatment prostate volume 
on urinary quality of life after intensity-modulated radiation therapy (IMRT) for clinically 
localized prostate cancer.
Methods: A total of 368 men treated with prostate IMRT (77.4–81 Gy) were stratified into three 
gland volume groups, ie, ,30 g (group 1), 30–60 g (group 2), and .60 g (group 3). Post-IMRT 
urinary function was evaluated by National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0 genitourinary guidelines at one year post-IMRT, and 
surveyed by the International Prostate Symptom Score (IPSS) before treatment, and then at one 
month and one year post-IMRT.
Results: Late (one year post-IMRT) CTCAE version 4.0 genitourinary toxicity occurred in 
11/368 (3.0%) men, but was not severe (grade $ 3); total toxicity was similar between the pros-
tate volume groups (P = 0.86). Continuous prostate volume neither correlated with (P = 0.50) 
nor predicted late genitourinary toxicity (univariate odds ratio 0.99, 95% confidence interval 
0.96–1.02). The total IPSS cohort, group 1 (,30 g) and 2 (30–60 g), showed a similar IPSS 
trend of elevation from pretreatment baseline to one month post-IMRT (each P , 0.01), then a 
reduction to baseline at one year (each P , 0.01). Group 3 (.60 g) had the highest pretreatment 
IPSS, but uniquely showed a better urinary symptom trend than the smaller volume groups, with 
similar IPSS from baseline to one month post-IMRT (P = 0.88) and improved post-treatment 
IPSS from baseline at one year (P = 0.003).
Conclusion: Pretreatment prostate volume and initial IPSS scores were not associated with 
increased late genitourinary toxicity after IMRT in our series. Patients with smaller prostates 
had an initial increase in urinary symptoms, but returned to baseline at one year. Larger prostate 
glands (.60 g) had comparatively worse pretreatment symptoms, but at one year showed an 
overall improvement in IPSS versus baseline.
Keywords: prostate, volume, radiation, intensity-modulated radiation therapy, urinary,   International 
Prostate Symptom Score, toxicity, Common Terminology Criteria for Adverse Events
Background
Prostate cancer is the leading nondermatological cancer and the second most common 
cause of cancer death in US males, with an estimated 2011 incidence and mortality of 
240,890 and 33,720 men, respectively.1 External beam radiation therapy (EBRT) is one 
of the conventional curative treatment options for localized prostate adenocarcinoma, 
along with brachytherapy and radical prostatectomy. Because the overall oncological 
outcomes are similar between the different treatment options, there has been increas-
ing focus on toxicity outcomes. Although high precision, tighter treatment margins, 
and better sparing of the bladder and rectum are advantages of intensity-modulated 
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radiation therapy (IMRT), gastrointestinal and genitourinary 
toxicities are important treatment concerns.2–4 Pretreatment 
prostate gland volume has consistently been shown to predict 
genitourinary toxicity after brachytherapy,5–8 likely due to a 
combination of both procedural trauma and radiation effects. 
More recently, pretreatment prostate size has come under 
investigation, with potential implications for post-EBRT 
urinary toxicity and quality of life.
We are aware of only two studies reporting the impact 
of pretreatment prostate volume on EBRT-associated 
genitourinary toxicity and bothersome urinary symptoms. 
Pinkawa et al9 compared small prostates (11–43 cm3) and 
large prostates (44–151 cm3), and found that the latter had 
more bothersome urinary symptoms pretreatment and on the 
last day of three-dimensional conformal radiation therapy; 
however, prostate volume did not differentially impact 
urinary health-related quality of life scores from 2 months 
after completion of radiotherapy.9 Subsequently, Aizer et al10 
reported that patients with prostate volumes above 50 cm3 
had higher rates of acute severe genitourinary toxicity, but 
late genitourinary toxicity was not addressed.
In order to inform patients about the side effects of 
radiotherapy and expectations for recovery, we analyzed 
acute and late urinary toxicity in a group of consecutively 
enrolled men. The aim of this study was to examine and 
describe the effect of pretreatment prostate volume, using 
three size groups (,30 g, 30–60 g, and .60 g), on pro-
gression of urinary symptoms and severity of late urinary 
toxicity after completion of IMRT. We hope to incorporate 
our findings into evidence-based counseling before patients 
commence IMRT.
Materials and methods
Patients and study design
This study was approved by the institutional review board at 
the University at Buffalo School of Medicine and Biomedical 
Sciences. We retrospectively reviewed the electronic medi-
cal records of 368 consecutive men treated with IMRT for 
clinically localized prostate cancer at two radiation oncology 
facilities. No patients had had prior EBRT or brachytherapy. 
All patients had transrectal ultrasound prostate volume mea-
surements at the time of prostate biopsy. Prostate volume was 
calculated by the height × width × length formula using the 
ultrasound computer. These volume measurements were used 
to stratify patients into three prostate size groups, ie, ,30 g 
(group 1), 30–60 g (group 2), and .60 g (group 3). Volume 
group cutoffs were selected in 30 g increments because 
the upper standard deviation from the total cohort mean 
(41.2 ± 20.9 g) was approximately 60 g; furthermore, our 
largest volume group threshold of 60 g has been reported as 
the upper size limit for prostate brachytherapy, beyond which 
adverse urinary symptoms, such as prolonged retention, are 
increased compared with smaller prostates.11
Radiation treatment
Radiation was delivered using IMRT and daily imaging, 
with 77.4–81 Gy in 180 cGy daily fractions prescribed for 
the planning target volume. Three gold fiducial markers were 
placed into the prostate gland prior to treatment and were 
used for daily imaging with either orthogonal kV imaging 
or cone-beam computed tomography. Patients underwent 
a computed tomography simulation in the supine position 
with a comfortably full bladder and an evacuated rectum 
from a bowel preparation starting 12 hours previously. Most 
patients underwent a planning magnetic resonance imaging 
scan for better visualization of the prostate. The planning 
target volume was created by applying a 7 mm margin around 
the prostate in all directions except posteriorly, where only 
a 5 mm margin was applied. Planning optimization used 
common criteria to evaluate the treatment plan, as previously 
reported.12 The patients were treated using Varian iX or Var-
ian Trilogy linear accelerators (Varian Medical Systems, 
Palo Alto, CA). IMRT treatment delivery was via VMAT 
using RapidArc or a static 7 field IMRT technique. Both 
techniques used 6 MV photons. Neoadjuvant, concurrent, or 
adjuvant hormonal therapy was initiated as deemed clinically 
appropriate, for a recommended duration of 2 years, as per 
our institutional best practice standards.
Symptom progression and late toxicity
In order to quantify the effects of IMRT on urinary quality of 
life, post-treatment adverse urinary outcomes were evaluated 
by two modalities, ie, National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) version 
4.0 guidelines13,14 and the validated International Prostate 
Symptom Score (IPSS) questionnaire.15,16 Genitourinary 
toxicity defined per CTCAE version 4.0 was graded in all 
368 men of the initial cohort at one year after completion 
of the IMRT treatment course. In order to trend urinary 
symptoms, we used the IPSS, which calculates a numeric 
score using seven questions, each answered on a 0–5 scale, 
that target the spectrum of lower urinary tract symptoms, 
ie, incomplete emptying, frequency, intermittency, urgency, 
weak stream, straining, and nocturia. IPSS values (potential 
score range 0–35) are symptomatically categorized as mild 
(0–7), moderate (8–19), or severe (20–35). We defined late 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
30
Chevli et alResearch and Reports in Urology 2013:5
genitourinary toxicity as those symptoms present beyond 
90 days after IMRT completion and measured at one year 
post-IMRT. IPSS scores and CTCAE toxicity grades were 
obtained prospectively for all patients.
Statistics
Statistical analysis was performed using the IBM® Statisti-
cal Package for the Social Sciences® (SPSS Inc, Chicago, 
IL) version 19.0 software. Continuous pretreatment vari-
ables (age, prostate volume) were expressed as means and 
compared between the prostate volume groups by one-way 
analysis of variance with Bonferroni multiple comparisons 
testing. Categorical pretreatment variables (clinical stage, 
total Gleason score, alpha-adrenergic blocking therapy, hor-
monal therapy, prior transurethral resection of the prostate or 
transurethral microwave thermotherapy, IMRT prescription 
dose) and CTCAE genitourinary toxicities were expressed 
as percentages and compared between volume groups by 
Chi-square test. Univariate logistic regression analysis was 
used to assess the impact of prostate volume as a continu-
ous variable and other pretreatment factors on prevalence 
of CTCAE genitourinary toxicity. Before and after volume 
stratification, repeated-measures one-way analysis of vari-
ance was used for comparison of absolute mean IPSS values 
across measured time points within each group, and the 
significance of IPSS differences between any two time points 
was assessed using the paired t-test. The Kruskal–Wallis test 
was used to compare IPSS and ∆IPSS (post-treatment minus 
pretreatment IPSS) medians between the volume groups, and 
the Mann–Whitney test was used for multiple comparisons of 
IPSS measures reaching significance on the Kruskal–Wallis 
test. The Pearson correlation was used to measure the strength 
of linear dependence between two variables. All reported P 
values are two-sided. Statistical significance was considered 
at P , 0.05.
Results
For the initial 368 male cohort, mean age at treatment was 
68.4 ± 7.8 (range 47–87) years and overall mean prostate 
volume was 41.2 ± 20.9 (range 7.1–161) g. Tumor stage 
T1C and Gleason grade 3+3 were most common (68.5% 
and 59.5%, respectively). Group 1 (prostate volume , 30 g) 
comprised 128 men with a mean gland size of 23.1 ± 4.7 g; 
group 2 (prostate volume 30–60 g) comprised 185 men with 
a mean gland size of 42.2 ± 8.5 g; and group 3 (prostate 
volume . 60 g) comprised 55 men with a mean gland size 
of 80.0 ± 18.5 g. Table 1 shows the available pretreatment 
patient characteristics across the prostate volume groups; 
prostate size and percentage of patients on alpha-blocker 
therapy were significantly different (each P , 0.01) between 
the volume groups; treatment age was significantly different 
between group 1 and other groups (P , 0.01), but age at treat-
ment between groups 2 and 3 was similar (P . 0.1). Other 
pretreatment factors were similar across the groups. Fifteen 
men with incomplete IPSS surveys were excluded from 
IPSS-based analyses; mean prostate volumes and statistical 
relationships of pretreatment variables were maintained from 
the initial patient group to the 353 male IPSS cohort.
CTCAE analysis of genitourinary toxicity
A total of 11/368 (3.0%) men developed CTCAE ver-
sion 4.0 genitourinary toxicity at one year follow-up, but 
none above grade 2 (see Table 2). No difference in total 
genitourinary toxicity was noted between the three volume 
groups (P = 0.86, Chi-square test). In the nine patients who 
developed grade 1 toxicity, median prostate volume was 34.3 
(range 10–72) g. The prostate volumes of the two patients 
with grade 2 toxicity were 20.2 g and 57 g. No correlation 
was observed between pretreatment prostate volume as 
a continuous variable and CTCAE genitourinary toxicity 
(P = 0.50, Pearson correlation). Using univariate logistic 
regression, continuous pretreatment gland volume did not 
predict genitourinary toxicity at one year post-IMRT (odds 
ratio [OR] 0.99, 95% confidence interval [CI] 0.96–1.02; 
P = 0.50).
Analysis of urinary symptom progression 
using iPSS
The overall median pretreatment IPSS score was 7 (range 
0–32), at one month post-treatment was 10 (range 0–35), 
and one year post-treatment was 6 (range 0–31). After 
prostate volume stratification, median pretreatment IPSS 
increased with prostate size, ie, group 1 (,30 g) 6.0, group 
2 (30–60 g) 7.0, and group 3 (.60 g) 12.0 (P , 0.01, see 
Table 3 for ranges). Median one-month IPSS was 10.0 for 
each prostate volume group (P = 0.87); median one-year 
IPSS was also similar across groups, ie, 5.0 for group 1 and 
7.0 for groups 2 and 3 (P = 0.053). Overall median IPSS 
increased from baseline to one month (∆IPSS1 month) by 2.0 
(range −22 to 21). Median ∆IPSS1 month for group 3 was −1.0 
and significantly improved (negative ∆IPSS indicates urinary 
symptom improvement from baseline) compared with the 
other groups (P = 0.001); median ∆IPSS1 month for groups 
1 and 2 was similar (4.0 and 2.0 respectively, P = 0.11). 
Overall, there was no change in median IPSS from baseline 
to one year (∆IPSS1 year = 0.0, range −24 to 20). There was a 
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statistically significant decrease in median IPSS scores only 
in group 3 prostates from baseline to one year (P = 0.003). 
This represents no change in IPSS scores for small (,30 g) 
and medium (30–60 g) prostate sizes at one year, and repre-
sents a median IPSS improvement of −3.0 in large (.60 g) 
prostate sizes at one year.
The collective cohort and group 1 (,30 g) and 2 (30–60 g) 
showed similar mean IPSS trends across the follow-up 
points (see Figure 1); after IPSS elevations from pretreat-
ment baseline to one month post-IMRT (each P , 0.01), 
a reduction to baseline values was observed at one year 
post-treatment (each P , 0.01). Pretreatment and one-year 
post-treatment IPSS values were similar for the ungrouped 
collective cohort (P = 0.15), and for group 1 (P = 0.63) and 
group 2 (P = 0.49). Group 3 (.60 g) had the highest mean 
pretreatment IPSS (P , 0.01) but did not show a one-month 
Table 1 Pretreatment patient factors
Pretreatment factor Group I (,30) Group II (30–60 g) Group III (.60 g) P
No pts 128 185 55
Race (%)
  White 74.2 67.0 70.9
  Black 4.7 1.6 5.5
  Hispanic 0 2.7 0
  Not reported 21.0 28.6 23.6
Age (yrs) 66.1 ± 8.5* 69.4 ± 7.4 70.5 ± 6.3 ,0.01*
Prostate Volume (grams) 23.1 ± 4.7 42.2 ± 8.5 80.0 ± 18.5 ,0.01
Clinical stage (%) 0.45
  T1-T2a 93.8 94.6 98.2
  T2b-T3 6.3 5.4 1.8
Gleason score, sum (%) 0.92
 # 7 88.3 89.7 89.1
 # 8 11.7 10.3 10.9
Alpha-blocker (%) ,0.01
  Yes 14.1 17.3 40.0
  No 85.9 82.7 60.0
Hormonal therapy (%) 0.39
  Yes 9.4 14.6 12.7
  No 90.6 85.4 87.3
Prior TURP (%) 0.31
  Yes 7.0 3.2 5.5
  No 93.0 96.8 94.5
Prior TUMT (%) 0.93
  Yes 1.6 2.2 1.8
  No 98.4 97.8 98.2
  iMRT prescription dose (%) 0.25
  77.4 Gy 75.0 82.7 78.2
  79.2-81 Gy 25.0 17.3 21.8
Notes: Continuous variables were compared by one-way ANOVA with Bonferroni multiple comparisons testing and categorical variables were compared by Chi-Square 
test (P , 0.05 considered significant for all analyses). *Mean treatment age is different between groups I v. II (P , 0.01) and i v. iii (P , 0.01), but similar between groups ii v. 
iii (P . 0.1).
Abbreviations: TURP-transurethral resection of the prostate; TUMT, transurethral microwave thermotherapy; iMRT, intensity modulated radiation therapy.
Table 2 CTCAE genitourinary (GU) toxicity one year after iMRT
GU toxicity grade  
(CTCAE v4.0)
Group I (,30 g) Group II (30–60 g) Group III (.60 g) Total cohort 
(N = 368)
0 124 (96.9%) 179 (96.8%) 54 (98.2%) 357 (97.0%)
1 3 (2.3%) 5 (2.7%) 1 (1.8%) 9 (2.5%)
2 1 (0.8%) 1 (0.5%) 0 2 (0.5%)
$3 0 0 0 0
Any toxicity* (Grade . 0) 4 (3.1%) 6 (3.2%) 1 (1.8%) 11 (3.0%)
Notes: CTCAE toxicity grading: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = life-threatening; 5 = death. Percentages = (# patients with toxicity grade)/(total # of patients 
in group). *Any toxicity (grade . 0) between the 3 volume groups not different by Chi-Square test (P = 0.86).
Abbreviations: CTCAE, common terminology criteria for adverse events; iMRT, intensity-modulated radiation therapy.
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Table 3 Median iPSS and iPSS between prostate volume groups
IPSS Group I (,30 g) Group II (30–60 g) Group III (.60 g) P‡
Pretreatment 6.0 7.0 12.0 ,0.01
(range: 0–32) (range: 0–32) (range: 0–28)
1 month post-tx 10.0 10.0 10.0 0.87
(range: 0–35) (range: 0–35) (range: 0–32)
1 year post-tx 5.0 7.0 7.0 0.053
(range: 0–31) (range: 0–25) (range: 1–31)
∆iPSS1 month 4.0 2.0 −1.0* 0.001*
(range: −16 to 20) (range: −18 to 21) (range: −22 to 19)
∆iPSS1 year 0.0 0.0 −3.0* 0.003*
(range: −15 to 20) (range: −24 to 16) (range: −23 to 19)
Notes: Total iPSS cohort N = 353 men. ‡Kruskal–Wallis test was used for comparison of median iPSS and ∆iPSS values across the 3 volume groups, P , 0.05 
denotes significant difference across groups. *Mann–Whitney multiple comparisons testing: ∆iPSS1 month is different between groups iii v. i (P , 0.01) and iii v. ii   
(P , 0.01), but similar between groups i v. ii (P = 0.11); ∆iPSS1 year is different between groups iii v. i (P , 0.01) and iii v. ii (P , 0.01), but similar between groups 
i v. ii (P = 0.61).
Abbreviation: iPSS, international prostate symptom score.
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post-treatment symptom spike, instead remaining stable for 
pretreatment and one month post-treatment IPSS (P = 0.88). 
Group 3 showed a mean IPSS reduction from one month to 
one year post-treatment that was similar to that in the other 
two volume groups (P = 0.40); however, the largest volume 
group uniquely showed a mean one-year post-treatment IPSS 
that improved beyond its baseline (P = 0.003).
For the ungrouped collective cohort, pretreatment IPSS 
correlated positively (r = 0.28) with pretreatment prostate 
volume (P , 0.01, Pearson correlation); after volume 
stratification, this correlation was more pronounced (r = 0.44) 
only in the largest volume group (P , 0.01). Group 3 also 
showed a positive correlation (r = 0.36) between one-year 
post-treatment IPSS and pretreatment volume (P = 0.01). 
Absolute one-month and one-year post-treatment IPSS val-
ues were similar between the volume groups (P = 0.87 and 
P = 0.053, respectively). Total CTCAE genitourinary toxicity 
in this cohort was 10/353 (2.8%). Pretreatment IPSS did not 
correlate with CTCAE genitourinary toxicity at one year 
post-treatment (P = 0.50), and did not predict for toxicity on 
univariate logistic regression (OR 1.05, 95% CI 0.96–1.1, 
P = 0.30). One-year post-IMRT IPSS in the patients with 
CTCAE genitourinary toxicity was significantly higher than 
in the men without genitourinary toxicity (12.0 ± 6.1 versus 
7.7 ± 5.9, P = 0.03).
Analysis of remaining pretreatment 
variables
The remaining pretreatment variables (ie, age and categorical 
factors, as shown in Table 1) were evaluated for interaction 
with CTCAE genitourinary toxicity and IPSS trends. In the 
initial cohort, pretreatment alpha-blocker therapy predicted 
for increased CTCAE genitourinary toxicity on univariate 
logistic regression (OR 3.6, 95% CI 1.1–12.2; P = 0.04); 72 
of 368 (19.6%) men received pretreatment alpha-blockers, 
including five of the 11 (45.5%) men who developed CTCAE 
genitourinary toxicity. Patients who received pretreatment 
alpha-blocker therapy had a larger mean pretreatment pros-
tate volume than those who did not (50.9 ± 27.5 g versus 
39.1 ± 18.5 g, P , 0.01). In the ungrouped collective IPSS 
cohort, pretreatment alpha-blocker therapy showed a sig-
nificant association with measured IPSS values (P , 0.01 
for between-measurement effects, repeated-measures one-
way analysis of variance). Table 4 shows that 67 of 353 
(19.0%) patients on alpha-blockers started with a higher 
mean pretreatment IPSS, but experienced an attenuated rise 
in ∆IPSS1 month (P = 0.02) and improved ∆IPSS1 year (P = 0.02) 
compared with the men not on alpha-blockers. Use of an 
alpha-blocker did not show a confounding interaction with 
our prostate volume-stratified IPSS findings (P = 0.06 for 
between-measurement interaction effects, repeated mea-
sures one-way analysis of variance). Observed IPSS trends, 
including IPSS improvement in group 3 (.60 g), remained 
statistically significant after exclusion from IPSS cohort 
analysis of men on alpha-blockers. Because the volume 
group and alpha-blocker interaction approached significance 
(P = 0.06), a within-group analysis of alpha-blocker effects 
on IPSS was performed. Numbers of patients on pretreat-
ment alpha-blockers after volume grouping were as follows: 
group 1 (,30 g) 15/121 (12.4%); group 2 (30–60 g) 31/178 
(17.4%); and group 3 (.60 g) 21/54 (38.9%, P , 0.01 on 
Chi-square test). Only group 2 patients on alpha-blockers 
showed an improved mean ∆IPSS1 year versus their counter-
parts not on alpha-blockers (−3.9 ± 9.4 versus 0.39 ± 5.9; 
P = 0.02, unpaired t-test). Other pretreatment variables did 
not predict for CTCAE genitourinary toxicity on univariate 
analysis (each P . 0.1) and did not show a significant asso-
ciation with IPSS findings (each P . 0.1).
Discussion
Our study describes the impact of pretreatment prostate 
volume on progression of urinary symptoms and severity of 
late (one year post-treatment) urinary toxicity after IMRT 
monotherapy. The total National Cancer Institute CTCAE 
version 4.0 genitourinary toxicity in our series was exception-
ally low (3.0%), with no severe (grade $ 3) toxicity observed. 
Similarly low severe late genitourinary toxicity rates after 
IMRT have been described previously. Eade et al reported a 
0.5% risk of late grade 3 genitourinary toxicity after IMRT, 
using 3-year Kaplan–Meier estimates of a modified Radiation 
Therapy Oncology Group toxicity scale, and the risk of late 
grade $ 2 genitourinary toxicity was 3.5%.17 Mohammed 
et al reported an incidence of 4.1% for late Common Toxicity 
Criteria version 3.0 genitourinary toxicity grade $ 3 at 1.1 
years after IMRT.18 Appropriate time points for late toxicity 
Table 4 Total cohort mean iPSS by pretreatment alpha-blocker
IPSS Pretreatment alpha-blocker P
Yes 
(N=67)
No 
(N=286)
Pretreatment 12.2 ± 8.0   7.4 ± 5.9 ,0.01
1 month post-tx 12.7 ± 7.5 10.7 ± 6.8 0.04
1 year post-tx   9.5 ± 7.4   7.4 ± 5.5 0.03
∆iPSS1 month 0.49 ± 9.0   3.3 ± 6.8 0.02
∆iPSS1 year −2.6 ± 9.0 0.01 ± 5.6 0.02
Notes: Unpaired t-test was used for comparison of mean iPSS values between 
alpha-blocker treatment groups; P , 0.05 considered significant.
Abbreviation: iPSS, international prostate symptom score.
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outcomes in IMRT are still being resolved, and follow-up in 
our patient series beyond one year post-radiotherapy may 
bear witness to developing genitourinary toxicity.
No association between pretreatment prostate volume 
and genitourinary toxicity at one year post-IMRT was found 
in our patient series, with pretreatment prostate size neither 
correlating with (P = 0.63) nor predicting for (univariate 
OR 0.99, CI 0.96–1.02, P . 0.1) late CTCAE genitourinary 
toxicity. Pretreatment urinary symptom scores have been 
suggested to predict for post-treatment urinary toxicity.6,19 
In our IPSS cohort, pretreatment IPSS did not correlate with 
(P = 0.50) or predict for late CTCAE genitourinary toxicity 
(OR 1.05, 95% CI 0.96–1.1, P = 0.30); however, one year 
post-treatment, IPSS was expectedly higher in men with late 
CTCAE genitourinary toxicity (12.0 ± 6.1 versus 7.7 ± 5.9 in 
men without toxicity, P = 0.03).
We found that IPSS scores were worse at one month for 
smaller (#60 g) prostate sizes but stable for larger prostates. 
At one year, patients with smaller-sized prostates had IPSS 
scores which had returned to baseline, while those with larger 
prostate sizes had improved from their baseline IPSS scores. 
Similar results were reported by Pinkawa et al,9 who observed 
that their large (44–151 g) prostate group had lower/worse 
pretreatment urinary health-related quality of life bother 
scores compared with their small (11–43 g) volume group. 
Both prostate volume groups developed significantly more 
bothersome urinary symptoms only on the last day of three-
dimensional conformal radiation therapy, with comparatively 
worse symptoms in the large prostate group. Both groups 
had returned to their pretreatment bother levels at 2 months 
post-radiotherapy, but at 16 months, only the large prostate 
volume group experienced a significant three-point improve-
ment from pretreatment urinary function.
Furthermore, Malik et al19 have previously analyzed IPSS 
data combined from whole-pelvic radiotherapy and IMRT. 
Men with moderate to poor pretreatment urinary function, 
defined in the study as IPSS $ 15, showed a 5-week post-
EBRT IPSS drop of −2 points from a median pretreatment 
baseline IPSS of 18 (P , 0.01); at 40 months post-EBRT, 
there was an IPSS drop of −7 points from baseline (P , 0.01). 
Pretreatment IPSS in our study correlated directly with 
continuous prostate volume for the entire cohort (r = 0.28, 
P , 0.01) and more strongly within the largest volume group 
(r = 0.44, P , 0.01); accordingly, the post-treatment IPSS 
trends for the worst pretreatment urinary symptom group 
in the Malik et al study paralleled the IPSS findings in our 
largest (.60 g) volume group. Also, in the study by Malik 
et al, reductions from pretreatment IPSS occurred regardless 
of androgen deprivation therapy. This androgen deprivation 
therapy-independent post-radiotherapy IPSS improvement 
was affirmed in our study.
Possible mechanisms that may be contributing to urinary 
symptom improvement after EBRT have been suggested pre-
viously, and include patient subjectivity, radiation-mediated 
prostate gland cytoreduction, and alpha-blocking therapy.19 
Patients with large prostates and pre-existing severe urinary 
bother may be biased against the acute urinary morbidity from 
radiation and likely have well-ingrained lifestyle modifications 
that may prevent perception of added urinary insult from IMRT. 
The generally less common group of patients with a large 
prostate volume and minimal pretreatment urinary bother20 may 
experience post-IMRT urinary symptom profiles comparable 
with those of patients with smaller prostates. Acute urinary 
symptoms (dysuria, urgency, frequency) are transient and 
usually subside.21 In the largest prostate group, this recovery 
translated to symptom improvement beyond baseline because 
of IPSS stability at one month post-IMRT unique to this group. 
IPSS improvement after one month, by essentially the same 
magnitude in all size groups, may reflect recovery from uniform 
IMRT dosing across prostate volumes. The shrinking effect 
of radiotherapy on the prostate is a known clinical finding, 
secondary to cellular water loss and fibrosis.22,23 Recent studies 
show that IMRT induces volume decreases prominently in the 
peripheral zone (−20.3%, P , 0.001) and central gland (−8.4%, 
P , 0.005), with the main shrinking effect seeming to occur 
during IMRT.24,25 Applying these findings to our study, our 
group with the largest prostate volume may be experiencing 
more available cytoreduction during radiotherapy that is offset-
ting the IMRT-induced acute-phase edema or inflammatory 
reaction, allowing this group to remain acutely symptomatically 
stable from baseline. In contrast, smaller prostate groups may 
not experience adequate volume shrinkage to counteract the 
acute urinary morbidity from radiation.
Analysis of the remaining pretreatment factors in our 
study showed that patients on alpha-blockers generally had 
larger pretreatment prostate volumes (50.9 ± 27.5 g versus 
39.1 ± 18.5 g, P , 0.01). On univariate analysis, presence 
of alpha-blocker therapy predicted for increased CTCAE 
genitourinary toxicity (OR 3.6, 95% CI 1.1–12.2; P = 0.04); 
therefore, men with pretreatment urinary symptoms severe 
enough to need alpha-blocker therapy should be advised 
of the higher potential risk of genitourinary toxicity at 
one year post-IMRT. Use of alpha-blockers did not show 
a confounding interaction with the IPSS findings grouped 
according to prostate volume, and our observed trends in 
IPSS improvement remained statistically significant even 
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after exclusion of men on alpha-blockers from the IPSS 
cohort analysis. Although the collective group of patients on 
alpha-blocker therapy showed a comparatively smaller eleva-
tion in ∆IPSS1 month and improved ∆IPSS1 year (see Table 4), 
further volume-grouped analysis revealed that only group 2 
(30–60 g) patients using alpha-blocking therapy had such a 
similarly favorable IPSS trend relative to their counterparts 
not using alpha-blockers.
These data are important for several reasons. First of all, 
they represent a large number of patients in a community 
setting treated with IMRT and use both physician-scored as 
well as patient-scored toxicity metrics. Therefore, our find-
ings are very relevant for community physicians in discussion 
of treatment-related genitourinary toxicity in terms of what 
patients can potentially expect from radiotherapy for prostate 
cancer. We feel it is important that worse pretreatment IPSS 
did not predict for late CTCAE genitourinary toxicity and that 
pretreatment prostate size was also not associated with late 
genitourinary toxicity. Similarly, we found that IPSS scores 
returned to baseline at one year for small (,30 g) and medium 
(30–60 g) prostates and improved versus baseline for large 
(.60 g) prostates. This is valuable in counseling patients as 
to when they should expect genitourinary function to return to 
normal and is important in that patients with large prostates are 
not likely to have an increase in genitourinary toxicity at one 
month or to have an improvement in IPSS score at one year. 
These data are useful in helping patients decide on treatment 
options, especially given that brachytherapy is known to 
increase late toxicity in patients with large prostates.
One of the weaknesses of the study is its retrospective 
nature, although this weakness was in part tempered by 
prospective collection of IPSS. A shortcoming in our IPSS 
collection was not doing so during radiotherapy, which may 
have provided a useful datum point in trending progression 
of urinary symptoms. Also, we were unable to control for 
alpha-blocker usage. Our use of patient-subjective IPSS 
warranted addressing the potential influence of pretreatment 
alpha-blocker therapy, given that alpha-blocker therapy does 
not affect prostate volume and is a routine consideration dur-
ing radiotherapy,26–28 but investigating alpha-blocker effects 
was not a primary aim in this study. Therefore, an inherent 
analytic weakness is our lack of differentiation between types 
of pretreatment alpha-blocking medication, ie, prophylactic, 
symptomatic, or chronic.
Conclusion
Pretreatment prostate volume was not associated with 
increased late genitourinary toxicity after IMRT in our 
series. The observed urinary morbidity in our patients with 
smaller prostates (,60 g) was early and self-limiting; in 
comparison, larger glands (.60 g) had worse baseline 
urinary symptoms, but showed a distinctly more favor-
able symptom trend from pretreatment to one year post-
treatment.
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